Tandem Diabetes Care, Inc. TNDM

Updated: 17 Jun 2026

NASDAQ | Technology | Diabetes care medical technology

No signal published yet

We already track Tandem Diabetes Care and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Tandem Diabetes Care free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Technology
Sector
Diabetes care medical technology
We're already tracking Tandem Diabetes Care, Inc. — here are the latest events we've registered

Recent News

  • On June 5, 2026, the company announced it received CE Mark clearance in Europe for expanded indications of its automated insulin delivery systems. The approval allows the use of its t:slim X2 and Tandem Mobi systems for adults with type 2 diabetes and pregnant women with type 1 diabetes.

What Firelda Watch includes for Tandem Diabetes Care, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Tandem Diabetes Care, Inc. will be delivered in the same format.

Want to follow Tandem Diabetes Care, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Tandem Diabetes Care free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Tandem Diabetes Care, Inc. TNDM
Tandem Diabetes Care — follow and we'll monitor it
Follow Tandem Diabetes Care free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.